Physician profile
Katelyn E Lynch
NPI 1194977330
$12,354.77
in general payments reported to CMS, 2019-2025
27 companies · $1,463 in 2025
The $1,463 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,765 · 2022: $6,620 · 2023: $2,173 · 2024: $333 · 2025: $1,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,152 · Consulting Fee: $1,745 · Education: $42.50 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,152.09 |
| Consulting Fee | $1,745.00 |
| Education | $42.50 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $8,050.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $660.77 | 2022-2025 | Minimed 780g, Minimed 770g |
| Alexion Pharmaceuticals, INC. | $627.88 | 2025 | Strensiq |
| Insulet Corporation | $521.89 | 2022-2024 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $478.32 | 2021-2023 | Farxiga |
| Abbott Laboratories | $383.54 | 2022-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Lilly USA, LLC | $336.58 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $311.50 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $191.19 | 2022-2025 | |
| Cequr Corporation | $134.27 | 2022-2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $123.60 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.37 | 2021 | |
| Ascendis Pharma Endocrinology INC | $44.81 | 2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $44.41 | 2023 | |
| Mannkind Corporation | $42.50 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $37.32 | 2024-2025 | Evenity, Prolia |
| Grt US Holding, INC. | $31.61 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.43 | 2023 | |
| Ibsa Pharma INC. | $29.53 | 2021-2024 | Tirosint, Licart |
| Neurocrine Biosciences, INC. | $24.53 | 2025 | |
| Rgh Enterprises LLC | $23.00 | 2025 | |
| Sequel Med Tech, LLC | $22.24 | 2025 | Twiist |
| Madrigal Pharmaceuticals | $20.47 | 2025 | Rezdiffra |
| Kyowa Kirin, INC. | $17.63 | 2025 | |
| Antares Pharma, INC. | $16.18 | 2025 | Xyosted |
| Beta Bionics, INC. | $13.93 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Corcept Therapeutics | $13.67 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.